







J. Bettiol, M. Radermecker, J. Sele, M. Henquet,
D. Cataldo, R. Louis, Department of








Accepted for publication 14 June 1999
To cite this article:
Bettiol J., Radermecker M., Sele J., Henquet M., Cataldo
D. & Louis R. Airway mast-cell activation in asthmatics
is associated with selective sputum eosinophilia.
Allergy 1999, 54, 1188–1193.




in asthmatics is associated
with selective sputum
eosinophilia
Key words: asthma; eosinophils; neutrophils; sputum; tryptase.
Background: Tryptase is a serine endoprotease selectively
released from mast cells. Although mast cells are known to
be activated after experimental allergic provocation, their role
in naturally occurring asthma is still debated.
Methods: We have investigated the levels of tryptase in the
whole induced sputum collected from 51 asthmatics (31 atopic
and 20 intrinsic) seen in our outpatient clinic and 22 normal
nonatopic healthy volunteers. Tryptase was measured by a new
immunoassay based on B12 monoclonal antibody recognition of
total tryptase (UniCAP System, Pharmacia) with a sensitivity of
1 ng/ml.
Results: While being below the threshold of detection in all
normal volunteers, tryptase was detectable in the sputum from
9/51 asthmatics (18%) including five atopic and four intrinsic
asthma cases. In these patients, among whom three were
asymptomatic asthmatics, the values ranged between 1 and
6.1 ng/ml. The asthmatics with detectable sputum tryptase had
greater sputum eosinophil counts (P<0.05) but lower neutrophil
counts (P<0.05) than those in whom tryptase was undetectable.
When compared to control subjects, asthmatics without tryptase
had still greater eosinophil counts (P<0.0001) but also raised
neutrophil counts (P<0.05). No significant difference could be
found between asthmatics with tryptase and those without
tryptase with respect to the age, the baseline lung function, the
methacholine bronchial responsiveness, and the frequency of
treatment with inhaled steroids.
Conclusions: With the UniCAP System, tryptase was detectable in
the sputum from 18% of asthmatics irrespective of atopy and
current symptoms. Asthmatics with tryptase appeared to have a
selective increase in sputum eosinophil counts while those
without tryptase displayed a mixed sputum granulocyte infiltra-
tion with raised eosinophil and neutrophil counts.
1188
Because it generates a large array of potent mediators after an
IgE-mediated reaction, the mast cell has long been viewed as
a pivotal cell in the pathophysiology of atopic asthma (1).
Among the mediators secreted by mast cells is the 134-kDa
serine endoprotease tryptase. This protease accounts for up
to 20% of mast-cell protein content (2). In contrast to
histamine, which is released from mast cells but also from
basophils, tryptase is synthesized in negligible quantity in
basophils and therefore appears to be a selective marker of
mast-cell activation. Tryptase levels in BAL (3–5) and
sputum (6, 7) were shown to be increased in asthmatics
when compared to control subjects. If mucosal mast-cell
degranulation is a well-documented event after a local
allergenic provocation in experimental conditions (3, 8), it
remains largely unknown whether airway mast-cell activa-
tion occurring under natural circumstances is associated
with any particular asthma phenotype.
The purpose of our study was to assess the degree of
airway mast-cell activation by measuring sputum tryptase
levels in a large series of both atopic and intrinsic asthmatics
recruited from our outpatient clinic. We also sought to
establish whether the extent of mast-cell activation was
associated with any particular features of the sputum
cellular composition. Sputum levels of tryptase were
determined in this study with a new immunoassay recently
validated for serum measurements which allows detection
of total tryptase (9, 10).
Material and methods
Subject characteristics
Fifty-one asthmatic subjects (mean age [range]: 45 years [15–
75], male/female: 22/29) and 22 healthy nonatopic volun-
teers (mean age: 33 years [23–52], male/female: 13/9)
participated in the study. Asthmatics were recruited from
our outpatient clinic. Asthma was diagnosed on the basis of
a clinical history of recurrent wheeze, breathlessness, or
cough associated with bronchial hyperresponsiveness to
methacholine (PC20M<16 mg/ml) when baseline FEV1 was
i70% predicted or a significant reversibility of FEV1
(i15%) when the baseline FEV1 was <70% predicted.
Methacholine bronchial responsiveness was measured
according to a previously described protocol (11) with
slight changes in the concentrations used. The first
concentration to be inhaled was 0.06 mg/ml (instead of
0.03 mg/ml), and the challenge was carried out by suc-
cessive inhalations of fourfold increased concentrations
(instead of twofold) until a 20% fall in FEV1 had occurred or a
maximal methacholine concentration of 16 mg/ml had been
inhaled. Mean (range) baseline FEV1 was 86% predicted (32–
115) in asthmatics and 104% predicted (85–127) in control
subjects. Geometric mean (range) PC20M was 1.5 mg/ml
(0.04–16) in asthmatics and >16 mg/ml in healthy subjects.
Thirty asthmatics were diagnosed as atopic on the basis of a
positive skin prick test (wheal of >3 mm when compared to
negative control) to at least one of the following common
aeroallergens: house-dust mites; cat and dog dander; grass,
tree, and weed pollens; molds; and feathers. Eleven of the 51
asthmatics were treated with inhaled steroids. All the
subjects gave their written informed consent after the
protocol had been approved by the hospital ethics commit-
tee.
Sputum induction
The subjects were premedicated with 400 mg inhaled
salbutamol. Hypertonic saline (4.5%) was aerosolized by
ultrasonic nebulizer Ultra Ned 2000 (De Vilbiss), with
output set at 1.5 ml/min. The subjects wore a nose clip and
quietly inhaled aerosol through a mouthpiece for up to four
5-min periods. After each inhalation, the subjects rinsed
their mouths with water and dried them with tissue paper to
minimize contamination with saliva. Then they coughed up
sputum into a plastic container, which was immediately
placed on ice until processing. Peak expiratory flow rate was
measured after each 5-min inhalation period (Mini-Wright),
and if it was greater than 250 l/min, the challenge was
carried on. After challenge, the subjects were supervised for
at least 1 h, and PEF was monitored regularly.
Sputum processing
The whole sputum was transferred into 50-ml polypropy-
lene tubes (Becton Dickinson, Abingdon, UK) and weighed,
and an equal weight of 0.01 M dithioerythritol (DTE; Fluka,
Gillingham, Dorset, UK) solution added as a mucolytic. This
was vortexed for 10 s, rocked for 30 min at room tempera-
ture, and again vortexed for 10 s. The samples were then
filtered through a 70-mm strainer (Becton Dickinson), and
the collected fluid was centrifuged at 400 g for 10 min at
4uC. The supernatants were removed and stored at x20uC.
The cell pellets were resuspended in 1 ml of PBS without
Ca2+ and Mg2+, and cells were counted with a manual
hemocytometer. The differential cell count was performed
on cytospins stained with Diff Quick1 after counting 600
cells (excluding squamous).
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Tryptase assay
Tryptase was measured by a new commercially available
immunoassay, the monoclonal antibody of which recog-
nizes both the active b-tryptase and the inactive a-
protryptase (B12 monoclonal antibody, UniCAP System,
Pharmacia). To ensure adequate recovery of tryptase in the
sputum samples, we performed spiking experiments by
adding known concentrations of tryptase in a pool of sputum
samples without tryptase. The added concentrations were
2.5, 6.5, 25, and 100 ng/ml, and the recovered concentra-
tions were 2.3, 6, 22, and 105 ng/ml, indicating a recovery
close to 100%.
Statistical analysis
Cell counts and mediator levels were expressed as median
(range) and compared between asthmatics and healthy
subjects by nonparametric tests. Comparison between two
groups was performed with the Mann–Whitney test. When
three groups were compared together, we used the Kruskal-
Wallis test and, in case of significance, the Mann–Whitney
test to perform pairwise comparisons. Comparisons of age,
FEV1, and PC20M between asthmatics with tryptase and
those without tryptase were performed by the unpaired
Student’s t-test. Comparisons of qualitative parameters
such as atopy, smoking habits, and treatment by inhaled
steroids between tryptase-positive and tryptase-negative
asthmatics were performed by Fisher’s exact test.
Results
When compared to healthy subjects, asthmatics had a
greater proportion of eosinophils (P<0.0001) and neutro-
phils (P<0.05) in their sputum but a lower proportion of
macrophages (P<0.001). When results were expressed as
absolute values, asthmatics were still distinguished from
healthy subjects by increased eosinophil counts (P<0.0001)
(Table 1).
Tryptase was undetectable in all healthy subjects and
detectable in the sputum from only nine of 51 asthmatics
(Fig. 1). In these subjects, the values ranged from 1 to 6.1 ng/
ml. The subjects who had detectable levels of tryptase
included five atopic asthmatics and four intrinsic asth-
matics. Among the nine patients in whom tryptase was
found to be detectable, three had to be considered
intermittent atopic asthmatics as they reported symptoms
less than once per week. When compared to asthmatics
without detectable tryptase, those with detectable tryptase
in their sputum had a greater relative sputum eosinophil
count (9.2% [2.6–74] vs 2.4% [0.2–90], P<0.05) but a lower
relative sputum neutrophil count (16.2% [2.2–59] vs 44.2%
[0–94], P<0.05) (Fig. 2). When cell counts were expressed as
absolute values, this observation held for eosinophils
(P<0.05), but no longer for neutrophils (P=0.2). In asth-
matics, there was a significant positive correlation between
sputum tryptase levels and the sputum eosinophil count
however the eosinophil count was expressed (rs=0.41,
P<0.001 when expressed as a percentage and rs=0.31,







% Squamous cells 8.5 (0–29) 9 (2–29)
Total nonsquamous cellsr106/g 0.9 (0.06–3.4) 1.22 (0.06–8.9)
% Macrophages 56.4 (16.8–93) 33.4 (0–72)**
Macrophagesr103/g 517 (55–2238) 402 (0–2328)
% Lymphocytes 1.5 (0–5.2) 0.8 (0–12)
Lymphocytesr103/g 12 (0–150) 7 (0–331)
% Neutrophils 20.2 (0.8–81.4) 35.8 (0–99.4)*
Neutrophilsr103/g 226 (0–2751) 310 (0–8837)
% Eosinophils 0 (0–2.3) 3.2 (0.2–90)****
Eosinophilsr103/g 0 (0–34) 31 (1–4851)****
% Epithelial cells 9.8 (0.6–33.4) 6.4 (0–46.3)
Epithelial cellsr103/g 79 (1–431) 82 (1–581)
Results are expressed as median (range).
*Indicates significance vs healthy; *P<0.05, **P<0.01, and ****P<0.0001
(Mann–Whitney test).
Figure 1. Sputum tryptase levels in healthy subjects (circles) and
asthmatics (triangles). Detectable tryptase from atopic asthmatics is
indicated by solid triangles and that from intrinsic asthmatics by open
triangles. Dashed line represents sensitivity of immunoassay.
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P<0.05 when expressed as absolute value). In the same
group, sputum tryptase levels inversely correlated with the
sputum neutrophil count expressed as a percentage
(rs=x0.23, P=0.05), but not with neutrophils expressed
as absolute value (rs=x0.17, P>0.05). There was no
difference between the tryptase-positive and the tryptase-
negative asthmatics regarding the other cell types. When
compared to control subjects, asthmatics without tryptase
still had a clear increase in sputum eosinophil counts
(P<0.0001) but also a raised sputum neutrophil count
(P<0.05) (Fig. 2). This was still valid for the cell counts
expressed in absolute values (P<0.0001 for eosinophils and
P=0.06 for neutrophils, respectively).
There was no significant difference between the asth-
matics with and those without tryptase in their sputum
with respect to age (meantSD: 38t13.5 vs 45t17 years),
FEV1 (meantSD: 87t22 vs 86t19 years), PC20M (geometric
mean [range] 0.8 [0.05–14] vs 1.8 [0.04–16]), and the
frequency of treatment with inhaled steroids (1/9 vs 10/
42) (P>0.05 for all variables).
Discussion
Our study shows that tryptase was detectable in the sputum
of 18% of asthmatics, but this protease was virtually
undetectable in healthy volunteers. The presence of tryptase
in the sputum was found indiscriminately in atopic and
intrinsic asthmatics. Detectable levels of tryptase in
asthmatics were associated with prominent airway eosino-
philia without increased neutrophilia.
In this study, we found a relatively low percentage of
asthmatics with detectable levels of tryptase in their
sputum. This contrasts with some previous work, including
ours, reporting that tryptase was detectable in the whole
sputum of a majority of asthmatics (7, 12). Discrepancies
between previous reports and our present study might be
related to the type of immunoassay employed. Tryptase
exists in two distinctive forms, the active b-tryptase
secreted during mast-cell degranulation and the a-protryp-
tase constitutively released (2). In this study, we have used
for the first time a new immunoassay recognizing both
b-tryptase and a-protryptase (monoclonal antibody B12,
UniCAP System, Pharmacia), and therefore measuring
total tryptase, while the immunoassay used in previous
studies recognized only b-tryptase (G5 monoclonal anti-
body, RIACT, Pharmacia). This should have enhanced the
sensitivity of the assay, as has been demonstrated for serum
measurements. Indeed, the use of the B12 monoclonal
antibody allows the detection of tryptase in the serum of
normal subjects, unlike the G5 monoclonal antibody (9).
However, our data indicate that the increased sensitivity
found for serum measurements does not necessarily apply to
measurement in other biological fluids such as sputum.
This suggests that the inactive a-protryptase is not an
important component of the pool of tryptase in the airways,
as it is in the serum. While the sensitivity of the new
immunoassay based on the B12 monoclonal antibody is
1 ng/ml, the sensitivity of that based on G5 monoclonal
antibody (RIACT) was found to be 0.5 ng/ml. If this relative
loss in sensitivity for the b-tryptase may partly explain the
lower rate of tryptase-positive asthmatics in this study, it is
certainly not the major reason, as the majority of asthmatics
tested in previous studies with the RIACT were found to
have tryptase levels higher than 1 ng/ml (5, 12).
On the other hand, we do not believe that the use of DTE
as a mucolytic has adversely affected the immunoassay, as
spiking experiments in this study clearly show that treating
the samples with DTE allows a full recovery of tryptase. In
addition, tryptase levels in samples treated with DTE have
been found to be greater than in those treated with PBS (13).
Certainly, the best approach to analyze any difference
Figure 2. Sputum eosinophil (upper panel) and neutrophil counts (lower
panel) according to presence or absence of tryptase in fluid phase of
sputum samples. Horizontal bars represent median value.
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between the two immunoassays would have been to
compare their sensitivities in the same study, but, unfortu-
nately, the RIACT was no longer available by the time we
carried out this study. Instead, to establish the lack of
sensitivity of the immunoassay, we might also consider real
differences in the features of the airway inflammatory
process between asthmatics in this study and those
previously investigated. As local release of tryptase is well
documented after experimental mucosal allergen exposure
(3, 8), we can hypothesize that differences in the population
studied reflect varying degrees of natural allergen exposure.
It is worth noting, however, that tryptase could also be
detected in some of our asthmatics in whom no sensitiza-
tion to common aeroallergens was found by skin prick tests.
This emphasizes the similarities in the airway inflamma-
tory process found in atopic and ‘‘intrinsic’’ asthma (14), and
it also suggests that mast-cell activation may occur under
other circumstances than sole allergen exposure.
The interesting point of this study is the fact that
asthmatics with detectable levels of tryptase in their
sputum also had a greater eosinophil count but a lower
neutrophil count than those without tryptase. This associa-
tion between sputum tryptase levels and sputum eosinophil
counts is in line with reports showing a positive correlation
between mast-cell and eosinophil numbers infiltrating the
nasal epithelium in asthmatics sensitized to grass pollen
(15) as well as between BAL cell lysate histamine and BAL
eosinophil numbers in a heterogeneous group of asthmatics
(16). Taken together, these observations suggest a functional
relationship between airway mast-cell number and/or
activation and airway eosinophil recruitment and/or sub-
sistence. Recent in vitro findings lend support to this
hypothetic relationship. Tryptase, a product of mast-cell
degranulation, has recently been shown to be able to
stimulate eosinophil chemotaxis (17), and IL-5, which can
be released from mast cells after an IgE-mediated stimula-
tion (18), is a potent factor enhancing eosinophil chemotaxis
and survival (19).
On the other hand, the asthmatics with tryptase in their
sputum appeared to have a relatively low proportion of
neutrophils infiltrating their airways, an observation which
indicates that naturally occurring airway mast-cell activa-
tion is accompanied by selective eosinophilic inflammation.
The reason for this selective eosinophil recruitment is
unclear, but it might be related to the concomitant release of
mediators, such as histamine, that can inhibit neutrophil
chemotaxis (20). It is noticeable that asthmatics without
tryptase had a mixed airway granulocytic infiltration with
raised sputum eosinophil and neutrophil counts when
compared to control subjects. Thus, neutrophils seem to
migrate in the asthmatic airways as the role of mast cells in
the airway inflammatory process becomes less important.
This apparent antagonism between neutrophils and mast
cells has been recently documented in the airways of severe
asthmatics where eosinophils and neutrophils appear to
be abundant with a poor contribution of mast cells to
the inflammatory process (21). In our study, we could not
find significant differences between tryptase-positive and
tryptase-negative asthmatics in terms of age, baseline lung-
function impairment, and bronchial methacholine hyperre-
sponsiveness, but the study was not designed to look
specifically at severe asthmatics. It is worth noting that
among the nine asthmatics found to be tryptase positive,
three were asymptomatic, a fact which stresses that the
extent of mast-cell activation is poorly related to the clinical
severity of asthma. This is in line with a previous study
failing to show any relationship between the Aas score and
BAL tryptase levels in asthma (5), as well as with our recent
observation that sputum tryptase levels were not greater in
severe than intermittent asthma (22).
We conclude that, with the new UniCAP System based on
B12 monoclonal antibody, tryptase is detectable in approxi-
mately one-fifth of asthmatics while remaining undetect-
able in all healthy nonatopic subjects. In asthmatics,
tryptase can be detected in the sputum irrespective of
atopy or the presence of current symptoms. The presence of
tryptase is associated with a selective sputum eosinophilia,
while its absence coincides with a mixed granulocytic
infiltrate.
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